Lenacapavir is a long-acting injectable antiretroviral drug developed by Gilead Sciences. It is administered just twice a year and has demonstrated over 99.9% effectiveness in preventing HIV ...

Lenacapavir, approved by the FDA in June, requires only two shots a year. US insurers don't cover it, but access will soon ...

The CDC made a strong recommendation based on a high certainty of evidence to use the long-acting injectable lenacapavir ...

Gilead surges 26.5% YTD in 2025 as HIV franchise gains momentum with Yeztugo approval, offsetting cell therapy pressures.

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

The scope of FDA warnings about compounded drugs is narrower than messaging suggests, because they do not center on the ...

Gilead Sciences, Inc. (GILD) announced that the European Commission (“EC”) has granted marketing authorization to HIV prevention drug lenacapavir, under the brand name Yeytuo. The EC approved ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization for Yeytuo® (lenacapavir)—the company’s twice-yearly injectable HIV-1 capsid ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization for Yeytuo ® (lenacapavir)—the ...

CVS Health has denied coverage for a new HIV prevention drug despite it being nearly 100 percent effective, citing in part the medication's high cost. The nation's largest pharmacy benefit manager ...

– Positive Opinion Also Received for EMA’s EU-M4all Procedure, Designed to Facilitate Availability in Low- and Lower-Middle-Income Countries – The CHMP also adopted a positive EU-Medicines for all (EU ...